Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05662540
Other study ID # NK-PETMR
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 26, 2023
Est. completion date October 2026

Study information

Verified date June 2023
Source Ruijin Hospital
Contact Weili Zhao
Phone +862164370045
Email zwl_trial@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study intends to evaluate the application value of Positron Emission Tomography/Magnetic Resonance (PET/MR) in the staging and efficacy evaluation of NK/T cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.


Description:

Nature Killer/T-cell Lymphoma (NKTCL) is a highly heterogeneous, aggressive lymphoma subtype with poor prognosis. Ninty percent of patients have lesions involving the nasal region, other extranodal organs include adrenal glands, gastrointestinal tract, skin and so on. Local tumor infiltration (bone, skin, paranasal sinus, etc) is a poor prognostic factor. Therefore, NK/T-cell lymphomas have high demands on the resolution of fine anatomical structures. PET/CT and nasopharyngeal contrast-enhanced MR are routine examination methods for diagnostic staging and efficacy evaluation, but the images cannot be fused, and the divided examinations bring inconvenience to patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 2026
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender All
Age group 14 Years to 70 Years
Eligibility Inclusion Criteria: - Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016 - Age from 14 to 70 years-old - ECOG 0-2 score - Patients with a life expectancy of at least 6 months - Patient has not been treated before for NK/T cell lymphoma - Commit to abide by the research procedures and cooperate with the implementation of the whole process of research - Written informed consent Exclusion Criteria: - Subjects who meet any of the following criteria are not eligible for study entry - Diagnosed aggressive NK cell leukemia - Pregnant or lactating women - Liver and kidney insufficiency - Other PET/MR contraindications: 1. Those with implanted functional electronic devices such as cardiac pacemakers 2. Carotid aneurysm clipping and other implants are ferromagnetic materials 3. Implanted perfusion devices such as insulin perfusion pumps 4. Those who do not cooperate in examinations such as coma, mental illness, and critically ill patients 5. Those who are claustrophobic - Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study

Study Design


Intervention

Device:
Positron Emission Tomography/Magnetic Resonance (PET/MR)
18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.

Locations

Country Name City State
China Ruijin Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The sensitivity, specificity and accuracy of PET/MR in the staging of newly diagnosed NK/T-cell lymphoma patients SUVmax, organs, et al. Baseline
Primary The sensitivity, specificity and accuracy of PET/MR in the efficacy evaluation of newly diagnosed NK/T-cell lymphoma patients SUVmax, organs, et al. After at least 2 cycles
Secondary Exploratory construction of prognostic prediction or efficacy evaluation system for newly treated NK/T-cell lymphoma based on PET/MR imaging indicators. SUVmax, organs, progression-free survival, overall survival, et al. Baseline up to data cut-off (up to approximately 4 years)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03701022 - PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Phase 2
Recruiting NCT04490590 - A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Phase 4
Recruiting NCT05833893 - Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma Phase 2
Recruiting NCT06362148 - Circulating Tumor DNA in Peripheral T-cell Lymphomas
Completed NCT03012620 - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types Phase 2
Recruiting NCT04008394 - Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Phase 1
Active, not recruiting NCT04425070 - A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Phase 1/Phase 2